◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksE › EPIT

Epitomee Medical Ltd (EPIT) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-22

Epitomee Medical Ltd (EPIT) operates in the Medical Devices industry and is headquartered in Caesarea, Israel with about 44 employees. Its market capitalization is roughly ₪87 million. In the fiscal year ended 2025-12-31, EPIT reported $0M in revenue and ($9M) in net income.

Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.

Interactive charts & full statements →

EPIT Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$10M$0M
Gross Profit($1M)$0M
Operating Income (EBIT)($10M)($9M)$0M($11M)
Net Income($9M)($2M)($6M)($15M)

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

EPIT Free Cash Flow History

EPIT Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$33M$40M$40M$55M
Total Liabilities$7M$6M$6M$16M

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EPIT viewer.

Other Companies in Medical Devices

This page in other languages: עברית

← EPINAll “E” companiesEPMB →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.